1195 related articles for article (PubMed ID: 23291258)
1. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
2. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
[TBL] [Abstract][Full Text] [Related]
3. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
Katakami N; Tada H; Mitsudomi T; Kudoh S; Senba H; Matsui K; Saka H; Kurata T; Nishimura Y; Fukuoka M
Cancer; 2012 Dec; 118(24):6126-35. PubMed ID: 22674529
[TBL] [Abstract][Full Text] [Related]
4. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
5. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
6. The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.
Kim SH; Cho BC; Choi HJ; Chung KY; Kim DJ; Park MS; Kim SK; Chang J; Shin SJ; Sohn JH; Kim JH
Lung Cancer; 2008 Jun; 60(3):393-400. PubMed ID: 18155802
[TBL] [Abstract][Full Text] [Related]
7. Impact of adjuvant chemotherapy in stage IB non-small-cell lung cancer: an analysis of 112 consecutively treated patients.
Dediu M; Ion O; Ion R; Alexandru A; Median D; Gal C; Horvat T; Motas C; Motas N
J BUON; 2012; 17(2):317-22. PubMed ID: 22740212
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Asahina H; Sekine I; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
Clin Lung Cancer; 2012 Jan; 13(1):39-43. PubMed ID: 21890422
[TBL] [Abstract][Full Text] [Related]
9. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
10. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
[TBL] [Abstract][Full Text] [Related]
11. [Two patterns of mediastinal lymph node resection for non-small cell lung cancer of stage IIIA: survival analysis of 219 cases].
Zhang GQ; Han F; Gao SL; A DL; Pang ZL
Ai Zheng; 2007 May; 26(5):519-23. PubMed ID: 17672944
[TBL] [Abstract][Full Text] [Related]
12. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
Mouillet G; Monnet E; Milleron B; Puyraveau M; Quoix E; David P; Ducoloné A; Molinier O; Zalcman G; Depierre A; Westeel V;
J Thorac Oncol; 2012 May; 7(5):841-9. PubMed ID: 22722786
[TBL] [Abstract][Full Text] [Related]
13. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients.
Stefani A; Alifano M; Bobbio A; Grigoroiu M; Jouni R; Magdeleinat P; Regnard JF
J Thorac Cardiovasc Surg; 2010 Aug; 140(2):356-63. PubMed ID: 20381815
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
Park SH; Choi SJ; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Cho EK; Shin DB; Hoon Lee J
Cancer; 2007 Feb; 109(4):732-40. PubMed ID: 17211861
[TBL] [Abstract][Full Text] [Related]
15. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC.
Pezzetta E; Stupp R; Zouhair A; Guillou L; Taffé P; von Briel C; Krueger T; Ris HB
Eur J Cardiothorac Surg; 2005 Jun; 27(6):1092-8. PubMed ID: 15896624
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer.
Dy GK; Bogner PN; Tan W; Demmy TL; Farooq A; Chen H; Yendamuri SS; Nwogu CE; Bushunow PW; Gannon J; Adjei AA; Adjei AA; Ramnath N
J Thorac Oncol; 2014 Feb; 9(2):222-30. PubMed ID: 24419420
[TBL] [Abstract][Full Text] [Related]
17. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A
J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776
[TBL] [Abstract][Full Text] [Related]
19. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
[TBL] [Abstract][Full Text] [Related]
20. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.
Jaklitsch MT; Herndon JE; DeCamp MM; Richards WG; Kumar P; Krasna MJ; Green MR; Sugarbaker DJ
J Surg Oncol; 2006 Dec; 94(7):599-606. PubMed ID: 17039491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
